Tumor-penetrating therapy for β5 integrin-rich pancreas cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Delivery

Background:

• Pancreatic ductal adenocarcinoma (PDAC) exhibits significant desmoplasia and drug resistance, partly due to poor drug penetration into tumor tissue.
• Carcinoma-associated fibroblasts (CAFs) play a role in the tumor microenvironment and can influence tumor cell behavior.

Purpose of the Study:

• To investigate the role of beta5 integrin in PDAC progression and its potential as a drug delivery target.
• To evaluate the efficacy of the tumor-penetrating peptide iRGD in delivering payloads to PDAC.

Main Methods:

• Induction of beta5 integrin expression by CAFs in a TGF-beta-dependent manner was studied.
• The effect of beta5 integrin knockout on iRGD-mediated drug delivery and tumor progression was assessed in mouse models (KPC mice).
• Chemotherapy potentiation by iRGD was evaluated in KPC mice with varying beta5 integrin expression levels.

Main Results:

• CAFs induce beta5 integrin expression in PDAC cells via TGF-beta signaling.
• Beta5 integrin knockout in tumor cells reduced disease burden and improved survival in mice.
• iRGD-mediated delivery of conjugated and co-injected payloads was dependent on beta5 integrin expression.
• iRGD significantly enhanced co-administered chemotherapy in KPC mice with high beta5 integrin expression.

Conclusions:

• Beta5 integrin is crucial for PDAC progression and serves as an effective target for the iRGD peptide.
• iRGD-based drug delivery strategies can overcome poor drug penetration and potentiate chemotherapy in aggressive PDAC subpopulations.